Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of neutrophil migration. [GO_REF:0000058, GOC:TermGenie, PMID:1826836]
Neutrophil migration, a crucial component of the innate immune response, is a tightly regulated process involving a complex interplay of chemoattractants, adhesion molecules, and signaling pathways. The process can be broadly divided into several stages:
1. **Chemotaxis:** Neutrophils are attracted to sites of inflammation by chemoattractants, such as chemokines, complement components, and bacterial products. These chemoattractants bind to specific receptors on the neutrophil surface, triggering intracellular signaling cascades that activate the cell's motility machinery.
2. **Adhesion and Rolling:** As neutrophils approach the site of inflammation, they encounter vascular endothelial cells. They initially interact with the endothelium through selectins, which mediate rolling adhesion. This interaction slows down the neutrophils, allowing them to further engage with the endothelium.
3. **Tight Adhesion:** Once the neutrophils are rolling along the endothelium, they receive further signals from chemokines and other inflammatory mediators. These signals activate integrins, which are strong adhesion molecules. Integrin activation leads to tight adhesion of neutrophils to the endothelium.
4. **Transmigration:** After tight adhesion, neutrophils migrate across the endothelial barrier and into the inflamed tissue. This process, known as diapedesis, involves the reorganization of the cytoskeleton and the formation of pseudopodia, which allow the neutrophils to squeeze between endothelial cells.
5. **Migration toward the Chemotactic Gradient:** Once in the inflamed tissue, neutrophils follow the gradient of chemoattractants, moving towards the source of the inflammation. This directed migration is powered by the coordinated assembly and disassembly of the cytoskeleton, driven by signaling pathways activated by the chemoattractants.
6. **Phagocytosis and Degranulation:** At the site of infection or injury, neutrophils engulf and destroy pathogens through phagocytosis and release cytotoxic substances from their granules, such as reactive oxygen species and proteases. These activities help to eliminate the pathogens and contain the infection.
**Regulation of Neutrophil Migration:**
Neutrophil migration is tightly regulated by several factors:
- **Chemokines:** These small proteins are potent chemoattractants that act as the primary signals for neutrophil recruitment.
- **Complement Components:** Complement proteins, activated during inflammation, also act as chemoattractants and promote neutrophil adhesion.
- **Adhesion Molecules:** The expression and activation of adhesion molecules, such as selectins and integrins, are crucial for neutrophil rolling, tight adhesion, and transmigration.
- **Signaling Pathways:** A variety of intracellular signaling pathways, such as those involving G proteins, tyrosine kinases, and calcium signaling, are activated by chemoattractants and other stimuli, regulating the cytoskeleton and motility of neutrophils.
**Dysregulation of Neutrophil Migration:**
Dysregulation of neutrophil migration can lead to various pathologies, including:
- **Inflammatory Disorders:** Over-recruitment of neutrophils can contribute to chronic inflammation in conditions such as rheumatoid arthritis and inflammatory bowel disease.
- **Immunodeficiency:** Insufficient neutrophil migration can compromise immune defense against infections.
- **Cancer Metastasis:** Neutrophils can promote tumor growth and metastasis by aiding in tumor angiogenesis and immune suppression.
**In summary, neutrophil migration is a complex and precisely regulated process involving chemotaxis, adhesion, transmigration, and directed migration towards the source of inflammation. Dysregulation of this process can lead to a variety of diseases, highlighting the importance of understanding and controlling neutrophil migration in health and disease.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Ras-related C3 botulinum toxin substrate 1 | A Ras-related C3 botulinum toxin substrate 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P63000] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
ketorolac | 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively. ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed) | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
sanguinarine chloride | |||
chelerythrine chloride | |||
perifosine | ammonium betaine; phospholipid | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | |
ruboxistaurin | ruboxistaurin: inhibits protein kinase C beta; structure in first source | ||
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
sotrastaurin | sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients. sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source | indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines | anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent |
gdc-0973 | cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. cobimetinib: has antineoplastic activity; structure in first source | aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol | antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
azd5438 | sulfonamide | ||
nsc 23766 | NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1). Rac1 inhibitor : Any inhibitor of Rac1. | hydrochloride | antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist |
at13148 | |||
poziotinib | HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer | acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline | antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist |
bay 869766 | |||
gilteritinib | gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor | aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound | antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
glpg0634 |